Angiotech Pharmaceuticals, Inc. and partner Athersys, Inc. announced updated results from its phase I clinical trial of MultiStem(R), its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. T ... more
To use all functions of this page, please activate cookies in your browser.
